Nanobody-based bispecific antibody engagers targeting CTLA-4 or PD-L1 for cancer immunotherapy
Xin Liu, Camille M. Le Gall, Ryan Alexander, Ella Borgman, Thomas Balligand, Hidde L. Ploegh
Topics & Concepts
MedicineImmunotherapyCTLA-4Cancer immunotherapyAntibodyBispecific antibodyCancerTremelimumabPD-L1ImmunologyCancer researchImmune systemInternal medicineIpilimumabT cellMonoclonal antibodyMonoclonal and Polyclonal Antibodies ResearchImmunotherapy and Immune ResponsesCAR-T cell therapy research